Taurine Blocks a Key Aging Pathway to Protect Insulin-Producing Cells
New research shows taurine suppresses p53-driven senescence in pancreatic β-cells, offering a potential strategy to preserve insulin secretion with age.
Summary
Scientists discovered that taurine, a naturally occurring amino acid, protects pancreatic β-cells from senescence — a cellular aging process linked to type 2 diabetes. Using metabolomic profiling of mouse and human pancreatic islets, researchers found taurine levels rise in aged islets as a compensatory response but decline under diabetic conditions. In cell line experiments, taurine treatment reduced DNA damage markers, inflammatory cytokine expression (SASP), oxidative stress, and restored insulin secretion. Mechanistically, taurine enters β-cells via the SLC6A6 transporter and binds CDKN2AIP, blocking its interaction with p53 and promoting p53 degradation. These findings position taurine as a metabolite capable of targeting a central senescence pathway in β-cells.
Detailed Summary
Type 2 diabetes incidence rises sharply with age, partly because pancreatic β-cells — which produce insulin — undergo cellular senescence. Senescent β-cells exhibit hallmarks including pro-inflammatory secretion (SASP), cell cycle arrest, DNA damage, and oxidative stress, all driven in part by the tumor suppressor protein p53. Understanding what metabolic signals regulate p53 activity in β-cells could open new therapeutic avenues.
This study began with untargeted metabolomic profiling of pancreatic islets isolated from young (2-month-old) versus aged (18-month-old) male C57BL/6 mice, identifying hundreds of differential metabolites. Taurine and taurocholic acid emerged as among the most significantly upregulated compounds in aged islets. Parallel analysis of human pancreatic tissue showed taurine and its transporter SLC6A6 were elevated in older non-diabetic donors but substantially reduced in diabetic donors, suggesting a potential compensatory role that is lost in disease.
In vitro experiments using mouse MIN6 and rat INS-1E β-cell lines tested taurine (100 µM) against multiple senescence-inducing conditions: natural passage-associated aging, doxorubicin (DNA damage), and TNF-α (inflammatory cytokine). Across all models, taurine pretreatment reduced canonical senescence markers — SA-β-galactosidase activity, p53/p21 expression, γH2AX foci (DNA damage), and SASP cytokines (IL-1β, TNF-α, GDF15) — while also attenuating reactive oxygen species and restoring glucose-stimulated insulin secretion. Blocking SLC6A6 with the inhibitor taurocyamine abolished these effects, confirming that cellular uptake is required for taurine's actions.
To determine the molecular target, researchers combined LC-MS/MS intracellular taurine quantification, co-immunoprecipitation, drug affinity responsive target stability (DARTS), and limited proteolysis mass spectrometry (LiP-MS). These orthogonal approaches converged on CDKN2AIP (also known as CARF) — a positive regulator of p53 stability — as a direct binding partner of taurine. Taurine binding to CDKN2AIP disrupted its interaction with p53, accelerating p53 proteasomal degradation (confirmed via cycloheximide chase assays) and thereby suppressing the downstream senescent transcriptional program. This places taurine as a metabolic brake on a well-established aging pathway.
The study's implications are notable: taurine is a non-proteinogenic amino acid found in food (seafood, meat) and widely used as a supplement, with an established human safety profile. Augmenting taurine uptake in β-cells — either through dietary means or by enhancing SLC6A6 activity — may represent a feasible strategy to preserve β-cell function during aging and delay or prevent type 2 diabetes. However, the work was conducted in rodent cell lines and murine/human islet tissues without in vivo intervention studies, and dose translation to humans remains to be established.
Key Findings
- Taurine and taurocholic acid are significantly upregulated in aged mouse pancreatic islets by untargeted metabolomics.
- Taurine reduces p53/p21 expression, SA-β-gal activity, DNA damage, SASP cytokines, and ROS in β-cell senescence models.
- SLC6A6 transporter is required for taurine uptake; blocking it abolishes all anti-senescent effects.
- Taurine directly binds CDKN2AIP, disrupting its stabilization of p53 and accelerating p53 degradation.
- Taurine and SLC6A6 levels are reduced in human diabetic islets, suggesting a clinically relevant deficit.
Methodology
Untargeted metabolomics profiled islets from young vs. aged C57BL/6 mice; in vitro senescence was induced by doxorubicin or TNF-α in MIN6 and INS-1E cell lines. Taurine's molecular target was identified using co-immunoprecipitation, DARTS, and LiP-MS proteomics alongside LC-MS/MS intracellular quantification.
Study Limitations
All mechanistic experiments were performed in rodent β-cell lines and ex vivo islets without in vivo taurine supplementation trials to confirm metabolic benefits. The effective concentration used (100 µM) and translation to physiologically achievable human tissue levels requires further investigation. Human data are observational and based on relatively small donor cohorts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.